Aeglea Bio Therapeutics Inc

Change company Symbol lookup

Select an option...

AGLE Aeglea Bio Therapeutics Inc

CHH Choice Hotels International Inc

MAXN Maxeon Solar Technologies Ltd

GLBL Cartesian Growth Corp

MRNA Moderna Inc

SPUS.NV SP Funds S&P 500 Sharia Industry Exclusions ETF

EMCF Emclaire Financial Corp

SHOO Steven Madden Ltd

SEGI Sycamore Entertainment Group Inc

KVLQF ValOre Metals Corp

Go

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.